October 15, 2008 - Boston Scientific Corp. announced estimated U.S. market shares for September for its two drug-eluting stents (DES), based on preliminary data from Millennium Research Group (MRG), a provider of strategic information to the healthcare sector.
Based on the MRG data, the company estimates its share percentages of the U.S. DES market for September as follows:
- Boston Scientific’s PROMUS Everolimus-Eluting Coronary Stent System: 25 percent
- Boston Scientific’s TAXUS Express2 Paclitaxel-Eluting Coronary Stent System: 19 percent
Boston Scientific said the estimated aggregate U.S. market share for its two drug-eluting stents for the third quarter was approximately 45 percent, based on MRG data. The company reported the same aggregate U.S. market share for the second quarter.
Boston Scientific said it has introduced its TAXUS Express2 Atom Paclitaxel-Eluting Coronary Stent System to more than 500 accounts in the U.S. The TAXUS Atom stent is the only 2.25 mm diameter drug-eluting stent available in the U.S. The FDA approved the stent last month. It provides a drug-eluting stent treatment option for patients with small vessels for whom no DES was previously available. The Company said it is encouraged by the positive reception among clinicians for the TAXUS Atom stent.
For more information: www.bostonscientific.com
July 02, 2024 
